After reporting low efficacy results for its COVID-19 vaccine candidate, CureVac has appointed a new chief operating officer and made other changes in leadership. Sit back, relax, and enjoy BioProcess Insider’s Ins & Outs. CureVac entered the COVID-19 vaccine race in March 2020 when the German biotech received $88 million from the European Commission to expedite construction of a plant set to make a potential mRNA vaccine against coronavirus. In August 2020 with $213 million in IPO cash to fund the human…

Quantoom and eTheRNA have partnered to build RNA technology, which aims to produce affordable RNA-based therapies for distribution in 2023.   Under the terms of the agreement, eTheRNA will provide Quantoom Biosciences, a Univercells company, with all required material and data for the development of an RNA production system (RPS) in Belgium. The system aims to reduce cost through optimized processes and automation. Once the RPS is developed, Quantoom will be responsible for its global commercialization and both firms expect…

Inceptor Bio will collaborate with companies and academic institutions to develop multiple cell and gene therapy platforms to cure cancers. Inceptor Bio is creating the consortium to focus on specific technologies aimed at creating cures for various types of cancer. However, Inceptor did not disclose who the specific scientists, companies, and academic institutions they are working with are, but the project will be by its Advanced Manufacturing Platform (AMP+). The AMP+ cell and gene manufacturing site is being built at…

Lonza will develop an immunotherapeutic drug candidate for SelectImmune, an antibody for ValenzaBio and extends its collaboration with Pinteon. All in a week’s work for the Swiss CDMO. SelectImmune Pharma has collaborated with Swiss contract development manufacturing organization (CDMO) Lonza to develop processes for a novel immunotherapy protein drug (NIpD). “SelectImmune is developing NlpD, an anti-infectious and anti-inflammatory protein that is released by beneficial bacteria in our gut,” Yvette Stallwood, head of Applied Protein Services at Lonza told us. “This…

The agreement will advance AM-Pharma’s recAP program towards commercialization with KBI providing drug substance manufacturing and regulatory support. AM-Pharma’s recombinant human Alkaline Phosphatase (recAP) program is a potential treatment for Sepsis-Associated Acute Kidney Injury (SA-AKI). Acute kidney disease affects hundreds of thousands of people globally and currently has no authorized pharmacological treatments. Both firms partnered in 2011 to develop the program, which saw contract development manufacturing organization (CDMO) KBI Biopharma provide initial process development and manufacturing for early clinical use.…